On physical examination the patient was afebrile with blood pressure of 140/100 mmHg, heart rate 88 beats/minute, and respiratory rate 12/minute. There were classic sclerodermal skin changes with taut hidebound skin over the face, neck, extremities, anterior chest, and abdomen. The skin of the face was so retracted that the patient could not close her mouth over protruding upper incisors. Multiple telangiectasias were present on the face, but there were no signs of bleeding or ulcerations in the nostrils. Old, healed fingertip ulcerations were present without evidence of recent ischaemia. Chest examination showed clear lung fields with a normal cardiac examination. The abdomen was protuberant with a firm, non-tender palpable uterus up to the level of the umbilicus. Fetal movements were palpated, and auscultation showed fetal heart tones at greater than 120 beats/minute.
The patient was admitted to the high risk pregnancy service for further evaluation. A pelvic Pregnancy in a patient with scleroderma 777 examination performed by an obstetrician was unremarkable except for the gravid uterus. An ultrasound evaluation of the pelvis showed a healthy fetus estimated to be at 29 weeks' gestation. Admission laboratory tests showed a microcytic anaemia with haemoglobin 98 g/l, serum creatinine 88-6 tLmoVl, and blood urea nitrogen 8-8 mmol/l.
Urine protein was 0-295 g/24 hours, and calculated creatinine clearance was 58 ml/min. Pulmonary function testing indicated a mild restrictive ventilatory impairment with a reduced forced vital capacity (FVC), a reduced forced expiratory volume at 1 second (FEVy), and a normal FEV1/FVC ratio.
Concern about the possible harmful effects on the fetus of nifedipine and enalapril prompted a change of antihypertensive treatment to alpha-methyldopa 500 mg twice a day. On 18 April 1988 the patient was discharged only to return within 24 hours with vaginal bleeding. Readmission examination showed a blood pressure of 138/104 mmHg and 50% effacement of the cervix with no evidence of rupture of the fetal membranes. There was no evidence of fetal distress and no significant change in the patient's laboratory values. Intravenous magnesium sulphate was given for premature labour. The history of significant renal disease with hypertension and the failure of alpha-methyldopa to control the blood pressure adequately forced the decision to begin treatment with captopril 50 mg three times a day. By 28 April 1988 the patient had no evidence of progression of labour and was discharged from the hospital with good blood pressure control.
On 14 The use of angiotensin converting enzyme inhibitors during pregnancy is controversial with reports of increased risk of fetal wastage, teratogenic effects, fetal distress, and severe postpartum neonatal renal failure.9'3 There is one report of reversible acute renal failure in a neonate whose mother received enalapril for just 17 days before delivery. 14 Lindheimer and colleagues have suggested that angiotensin converting enzyme inhibitors should be contraindicated during pregnancy. '5 16 Responding to such reports, the United States Food and Drug Administration is developing new labelling that identifies angiotensin converting enzyme inhibitors as potentially harmful to the fetus for inclusion in drug package circulars. '7 In contrast, Coen et al have reported the successful birth of healthy twins to a mother who used captopril throughout gestation. 18 This patient, without scleroderma, who had longstanding hypertension and renal disease had suffered two previous spontaneous miscarriages due to uncontrolled hypertension. Captopril was found to be the only medicine that adequately controlled her blood pressure.
Our patient had taken enalapril and nifedipine until the 29th week of gestation when the pregnancy was discovered. Concern about potentially harmful effects on the fetus prompted a change of treatment to alpha-methyldopa, which did not adequately control the hypertension. In view of the past history of severe hypertension and scleroderma renal disease that was nQt easily treated the decision was made to use captopril. The patient was thus taking an angiotensin converting enzyme inhibitor for all but three days of her pregnancy. Because of the reported potential risks to the fetus with angiotensin converting enzyme inhibitors we cannot recommend their routine use during pregnancy. The treatment of our patient does show, however, that when the decision is made to use these drugs for the wellbeing of the mother a successful pregnancy is still possible.
This patient also shows that successful pregnancy can occur in scleroderma even after development of significant renal and pulmonary involvement. The combined evaluations by the high risk obstetric, rheumatology, and nephrology services, with frequent prepartum monitoring visits and noninvasive cardiopulmonary function testing, assisted in pregnancy management decisions. For example, the echocardiographic evidence of pulmonary hypertension led to the prophylactic measurement of pulmonary artery pressures during labour. Aggressive prenatal monitoring and the multidisciplinary team care approach seem to be prudent in the management of these patients with complications.
Finally, this unexpected pregnancy serves as a reminder that all sexually active young women with scleroderma should be counselled about birth control measures even in the presence of longstanding disease. Prevention of pregnancy in patients with scleroderma with significant cardiopulmonary or renal disease should be emphasised because of the great risk of increased maternal death. 
